Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial
2014 · The Lancet · 245 citations
https://doi.org/10.1016/s0140-6736(14)61185-5
S
Sarah H. Plummer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
29
Papers
4.3K
Citations
22
h-index
25
i10-index
Sarah H. Plummer is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Mosquito-borne diseases and control & Malaria Research and Control & Viral Infections and Vectors. The author has an h-index of 22, co-authored 25 publications.
Papers by this author
worksEffect of a Chikungunya Virus–Like Particle Vaccine on Safety and Tolerability Outcomes
2020 · JAMA · 103 citations
https://doi.org/10.1001/jama.2020.2477
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials
2024 · npj Vaccines · 18 citations
https://doi.org/10.1038/s41541-024-00833-z
Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine
2024 · npj Vaccines · 17 citations
https://doi.org/10.1038/s41541-024-00959-0
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat